High-affinity immunoglobulin E receptor (FcεRI) complexed with peanut-specific IgE (FcεRI-IgE complex)

The peanut-specific Immunoglobulin E (IgE) bound to the high-affinity IgE receptor (FcεRI) on mast cells and basophils is the primary molecular assembly responsible for peanut-induced allergic reactions (PubMed: 26453268). In sensitized individuals, peanut allergens (such as Ara h 1, 2, and 3) cross-link these IgE-FcεRI complexes, initiating a signaling cascade that involves Lyn and Syk kinases, ultimately leading to the rapid release of histamine and other inflammatory mediators (PubMed: 19442371). This process, known as degranulation, can cause symptoms ranging from mild skin reactions to systemic anaphylaxis. Therapeutic interventions often target this pathway by using monoclonal antibodies to sequester free IgE, preventing the formation of the complex and leading to the downregulation of FcεRI on effector cells (PubMed: 12756487). Additionally, oral immunotherapy (OIT) products like Palforzia aim to desensitize this system through controlled, incremental exposure to peanut proteins (FDA: Palforzia Prescribing Information). Monitoring this target involves measuring peanut-specific IgE levels and assessing basophil sensitivity to allergen challenge.

Other names

Peanut-specific IgE-FcεRI complexFc epsilon RI-IgE complexHigh affinity IgE receptor-immunoglobulin E complexPeanut-specific IgE-bound FcεRI

Therapeutic agents like Omalizumab bind to the Cε3 domain of free IgE, preventing its interaction with the FcεRI receptor on mast cells and basophils (PubMed: 12756487). This sequestration reduces the density of IgE-FcεRI complexes on the cell surface, thereby raising the threshold for allergen-induced degranulation (PubMed: 19442371).